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symptoms) were normal. Comparing endoscopic biopsy to 
nephroureterectomy specimen grade, 19 (46 %), 18 (44 %), 
and 4 (10 %) were identical, upgraded, and downgraded, 
respectively.
Conclusion Pre-operative investigations can predict 
UUTUCs. When these investigations were normal, the risk 
of UUTUC is negligible. In selective patients with abnor-
mal investigations, ureteroscopy should be performed to 
confirm and predict the grade of UUTUC, in order to guide 
future management. Selective cytology is unlikely to sig-
nificantly contribute to the diagnostic workup of UUTUC.
Keywords Upper urinary tract urothelial carcinoma · 
Ureteroscopy · Cytology · Endoscopic biopsy · Tumour 
grade
Introduction
Upper urinary tract urothelial carcinoma (UUTUC) is a rare 
malignancy, accounting for 5 % of all urothelial cancers 
[11]. Few useful prognostic factors have been established, 
and the 5-year specific survival remains low, at <50 % for 
pT2 and pT3 diseases, and <10 % for pT4 disease [6].
Radical nephroureterectomy (RNU) with excision of 
a bladder cuff remains the gold standard treatment for 
UUTUC, regardless of the location of the tumour in the 
upper urinary tract [9]; however, improvements in endo-
scopic techniques have led to increasing number of patients 
being managed endoscopically.
The natural history of UUTUC is still poorly under-
stood, and accurate risk stratification remains elusive. 
Attempts have been made to incorporate clinical and pre-
operative parameters into risk stratification tools [3, 13], 
which included urine cytology and imaging studies such as 
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multidetector computed tomography urography (MDCTU 
or CT) [4]. This is in addition to ureteroscopic findings, 
which have shown to be important in identifying and pre-
dicting the progression of UUTUC [2]. Early diagnosis 
is crucial to tailor individualised management plans and 
improve outcomes, and delays between diagnosis and sur-
gery have shown to have negative implications on disease 
recurrence and cancer-specific mortality [8].
Our study evaluates the diagnostic and prognostic value 
of the pre-operative and intra-operative parameters utilised 
in the investigation of UUTUC.
Patients and methods
Study population
We retrospectively analysed consecutive patients who under-
went ureteroscopy (URS) at our centre between January 
2005 and March 2014. Patients were referred to our urol-
ogy service with a suspicion of malignancy based on urinary 
tract symptoms (including haematuria, loin pain, and recur-
rent urinary tract infections). Following initial evaluation 
with flexible cystoscopy and upper tract imaging, patients 
were counselled and offered further upper tract assessment 
with rigid and/or flexible URS if they had abnormal cytol-
ogy, abnormal CT, ongoing haematuria, or abnormality 
from ureteric orifice at flexible cystoscopy. The diagnosis of 
UUTUC was based on the presence of distinct papillary or 
solid tumours observed on URS, and where available, his-
topathology results from ureteroscopic biopsies and nephro-
ureterectomy specimens. The medical charts, radiological, 
cytological, and pathological reports for all patients were 
independently reviewed by two authors (HD and SP). The 
clinicopathological parameters collected were gender; age 
and clinical presentations at diagnosis; previous history of 
bladder cancer; and patient treatment (endoscopic, radical 
surgery, or palliation). Twenty-six patients were excluded 
due to other malignancies or incomplete information (Fig. 1).
Pre-operative investigations
Both pre-operative ‘voided’ and intra-operative ‘selec-
tive’ cytology reports were assessed. Selective cytology 
was obtained during ureteroscopic washings of the renal 
pelvis and/or ureters. Cytology samples were classified as 
negative, atypical, and positive. Positive cytology was used 
when a high proportion of cells carried a high index of 
suspicion for malignant UUTUC, possessing exceedingly 
abnormal morphology. Atypical cytology was defined by 
the presence of a few abnormal cells, insufficient to exclude 
malignancy. CT reports were obtained prior to URS, and 
three main outcomes were evaluated: the presence or 
absence of (1) a filling defect or a soft tissue mass; (2) 
hydronephrosis/hydroureter; and (3) thickening of the ure-
teric wall. As such, an abnormal CT was defined as one 
which demonstrated a filling defect in the excretory phase, 
a visible mass in the region of the pelvis or ureter; hydro-
ureter/hydronephrosis or a ureteric stricture; a thickening of 
the ureteric wall with or without peri-ureteric stranding.
For each of these variables, the sensitivities and spe-
cificities were calculated, with respect to the presence of 
UUTUC, and for nephroureterectomy specimens with 
respect to tumour invasiveness.
Histopathological assessment
All biopsies and histopathological specimens were 
reviewed by our institution’s histopathologists, based on 
2004 World Health Organisation’s (WHO) and Interna-
tional Society of Uropathologists (ISUP) grading system 
[5, 7]. PUNLMP grades 1 and 2 were defined as low-grade, 
while grade 3 was classified as high-grade disease. Pathol-
ogy stage was used as a marker of tumour invasiveness 
[12], with invasive tumours defined as pT1 and above.
Statistical analysis
We performed Pearson’s Chi-squared tests to evaluate the 
relationship between pre-operative variables and intra-
operative variables, and calculated the sensitivities and 
specificities. We also conducted two separate multivariable 
regression analyses and calculated the corresponding area 
under the curve. All results were two-sided and deemed 
statistically significant if the p value <0.05. Statistical anal-
yses were performed using IBM SPSS Statistics for Win-
dows®, version 22.0. Armonk, NY: IBM Corp.
Results
Patients
Out of 186 patients who underwent diagnostic URS, 160 
patients were included in the analysis (Fig. 1). The patient 
characteristics, demographics, and presenting symptoms 
are outlined in Table 1. Patients underwent diagnostic URS 
(rigid ± flexible) if they had abnormal cytology (n = 59, 
51 %), abnormal CT (n = 135, 85 %), ongoing haematuria 
(n = 3, 2 %), or abnormality from ureteric orifice at flex-
ible cystoscopy (n = 2, 1 %). The proportion of patients 
who underwent each diagnostic investigation is shown in 
Supplemental Figure 1.
Hundred (63 %) patients had UUTUC confirmed at 
URS and/or after nephroureterectomy (Fig. 1). Malignancy 
was defined by the presence of UUTUC when directly 
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visualised, and where available, from biopsies taken endo-
scopically and/or confirmed after nephroureterectomy.
There was a general trend towards differing rates of pre-
vious bladder TCC between the benign cohort and those 
found to have an UUTUC (χ2 = 10.53, p = 0.062). Thirty-
three and 18 % of patients with or without an UUTUC had 
a prior history of CIS, grade 2 or grade 3 TCC of the blad-
der (see Supplemental Table 1).
Pre-operative investigations
Voided urine cytology was obtained in 116 (73 %) patients, 
of which 57 (49 %) were negative, 31 (27 %) were atypical, 
and 28 (24 %) were positive (Supplemental Figure 2a). 
Abnormal (i.e. atypical or positive) voided urine cytol-
ogy predicted the presence of UUTUC (χ2 = 10.165, 
p = 0.006) with a sensitivity and specificity of 63 and 
67 %, respectively, and predicted tumour invasiveness 
(χ2 = 6.67, p = 0.048). Figure 2 shows the proportions of 
each voided cytology parameter relative to the final histo-
pathological grade. Voided urine cytology was able to pre-
dict G2 and G3 diseases on final histopathological speci-
mens at 43 and 80 % sensitivities, respectively. In addition, 
voided urine cytology was also able to significantly predict 
selective cytology obtained endoscopically (Supplemental 
Figure 2c), with only 10 extra malignancies being identified 
186 consecuve paents 
underwent URS
26 paents were excluded
160 paents (105 men, 55 
women) met inclusion criteria
Review of medical charts, CT, 
cytology and histopathology 
reports
Unknown or unclear URS 
reports with no clear diagnosis 
(23)
Metastac pancreac cancer (1), 
small cell cancer (1), renal cell 
carcinoma (1)
Benign (60) Malignant (100)
Unknown management (7)
Nephroureterectomy (57)*
Endoscopic management, with 
rigorous follow-up (28)
Palliave management (8)
Fig. 1  Patient selection criteria. *2 of which were later confirmed to be benign on final histopathological analysis of nephroureterectomy speci-
mens
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by selective ureteroscopic washings. Of note, all of these 
ten additional patients also had abnormalities on CT (eight 
with filling defects or mass, one with ureteric thickening 
and one with hydronephrosis/hydroureter).
All 160 patients who underwent a URS had a CT, which 
identified a filling defect or mass in 100 (63 %) cases. The 
proportions of each parameter identified on CT imaging 
and their respective ability to predict UUTUC are sum-
marised in Table 2. Abnormal CT predicted UUTUC with 
a sensitivity of 95 % and specificity of 26 % (Table 2); 
however, CT findings were unable to predict tumour 
invasiveness (data not shown). Of the three CT parameters 
(filling defect or mass, ureteric thickening, or hydronephro-
sis/hydroureter) evaluated individually, a filling defect or 
soft tissue mass detected on CT was the only significant 
predictor of malignant status (χ2 = 15.213, p < 0.001). Five 
(25 %) patients with normal CTs had UUTUC identified 
on URS, while 15 (75 %) with normal CTs were correctly 
confirmed after URS; 42 (31 %) patients with abnormali-
ties on CT had a normal URS.
UUTUC was detected in 33/39 (85 %) patients who 
had filling defects or mass reported on CT together with 
abnormal voided urine cytology (17/20 with positive cytol-
ogy, and 16/19 with atypical cytology) (Table 3). Similarly, 
47/55 (85 %) patients were identified with UUTUC having 
had filling defects or mass on CT and abnormal selective 
cytology.
Eight (17 %) patients with positive voided cytology and 
abnormality on CT demonstrated a benign histology; six 
(75 %) of these had an identifiable filling defect or mass 
on CT.
Selective cytology
Selective cytology was obtained during URS in 126 (79 %) 
patients, where 55 (44 %), 27 (21 %), and 44 (35 %) were 
reported as negative, atypical, and positive, respectively. 
Selective cytology predicted UUTUC (χ2 = 30.866, 
p < 0.001) with a sensitivity and specificity of 76 and 73 %, 
respectively, in addition to predicting tumour invasive-
ness (χ2 = 8.608, p = 0.197) (Supplemental Figure 2b). 
Figure 2 shows the proportions of each selective cytology 
Table 1  Patient demographics and characteristics
(*) Denotes statistical significance (p < 0.05)
Variable Benign (%) Malignant (%) Total (%)
Total 60 (100) 100 (100) 160 (100)
 Male 33 (55) 72 (72)* 105 (66)
 Female 27 (45)* 28 (28) 55 (34)
Median age at presentation 
(IQR)
66 (50–76) 73 (66–81) 71 (61–78)
Presenting symptoms
 Haematuria 36 (60) 56 (56) 92 (58)
 UTI/loin pain 14 (23) 12 (12) 26 (16)
Associated history of blad-
der TCC
17 (28) 45 (45)* 62 (39)
Affected side
 Right 20 (33) 38 (37) 58 (36)
 Left 27 (45) 55 (55) 82 (51)
 Bilateral 13 (22) 7 (7) 20 (13)
Fig. 2  Distribution of voided 
and selective urine cytology 
results according to nephroure-
terectomy specimen grade
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outcome relative to the final grade from nephroureterec-
tomy specimens. The prognostic ability of selective cytol-
ogy was only marginally better than pre-operative voided 
cytology. In G2 and G3 nephroureterectomy specimens, the 
respective sensitivities for selective cytology was 65 and 
96 % compared with 43 and 80 % for voided urine cytol-
ogy (data not shown).
Of those with available selective cytology results and 
subtle CT findings (hydronephrosis/hydroureter or ureteric 
thickening only) (Table 2), eight had a benign outcome 
(with two abnormal and six negative selective cytology 
results); eight had a malignant outcome (four abnormal and 
four negative selective cytology results).
Ureteroscopic biopsy
Table 4 shows the histopathology from ureteroscopic biop-
sies and post-nephroureterectomy specimens, stratified 
according to grade and stage. Of 75 ureteroscopic biopsies 
that were taken, 65 (87 %) had UUTUC present. Of 59 
gradable specimens, 38 (64 %) were low-grade, while 21 
(36 %) were high-grade disease; 34 (64 %) tumours were 
invasive, and 19 (36 %) were non-invasive. Fifty-five out 
of 57 (96 %) nephroureterectomy specimens were identi-
fied as malignant; 2 (3 %) final cases had previously iden-
tified malignancy on URS, where the tumour was likely 
sufficiently removed by biopsy or diathermy rendering the 
final post-nephroureterectomy histopathological diagnosis 
as benign.
Ureteroscopic biopsy positively correlated with neph-
roureterectomy specimen in terms of grade (χ2 = 19.793, 
p = 0.071) and stage (χ2 = 19.950, p = 0.336) (Fig. 3). 
Nineteen (43 %) and 12 (32 %) biopsies matched the grade 
and stage of nephroureterectomy specimens. As expected, 
the proportion of biopsies that were upgraded and up-
staged was higher than those downgraded and down-staged 
(Fig. 3). Seven cases of 41 cases which could be analysed 
were upgraded to G2 or G3 disease (data not shown).
Multivariable analysis of pre-operative 
and intra-operative variables
Pre-operatively, male gender, age, voided urine cytology, 
and the presence of filling defect or mass on CT imaging 
were shown to be robust independent predictive factors of 
UUTUC, with the latter demonstrating the highest hazard 
Table 2  CT findings and 
prediction of UUTUC
Malignant status is determined by the presence of UUTUC observed on URS and/or histologically defined 
from biopsies taken endoscopically or following nephroureterectomy. CT reports were available in 155 out 
of 160 patients. The term ‘abnormal’ refers to the detection of filling defect or soft tissue mass, hydrone-
phrosis/hydroureter or ureteric thickening on CT. Percentages of row totals are denoted in brackets. (*) 
denotes a statistically significant difference between columns
CT Malignant status (%)
Benign Malignant Total
Normal 15 (75)* 5 (25)* 20
Abnormal 42 (31)* 93 (69)* 135
 Hydronephrosis/hydroureter 16 (29) 39 (71) 55
 Ureteric thickening 12 (35) 22 (65) 34
 Filling defect or soft tissue mass 28 (28)* 72 (72)* 100
Total 155
Single findings on CT urogram Benign Malignant Total
Hydronephrosis 8 (47) 9 (53) 17
Thickening 5 (56) 4 (44) 9
Filling defect or soft tissue mass 12 (24)* 37 (76)* 49
Table 3  Correlations between 
CT imaging and cytological 
findings
CT Voided urine cytology (%) Selective urine cytology (%)
Negative Atypical or positive Negative Atypical or positive
Benign Malignant Benign Malignant Benign Malignant Benign Malignant
Normal 5 (100) 0 (0) 5 (71) 2 (29) 10 (100) 0 (0) 4 (80) 1 (20)
Relevant Pathology 9 (56) 7 (44) 2 (22) 7 (78) 6 (50) 6 (50) 2 (20) 8 (80)
Filling defect/mass 19 (53) 17 (47) 6 (15) 33 (85) 19 (61) 12 (39) 8 (15) 47 (85)
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ratios of 11.7 (Table 5); AUC 0.816 (95 % CI 0.73–0.90). 
Ureteric thickening and hydronephrosis/hydroureter on CT 
were not significant independent predictors of UUTUC.
Discussion
Our results confirm that, pre-operatively, voided urine 
cytology and the presence of filling defect or mass on CT 
are important positive findings in the investigation of sus-
pected UUTUC. In addition to gender and age, they were 
able to independently predict the presence of UUTUC.
There were high false-positive rates particularly from 
CT investigations and non-specific findings of hydrone-
phrosis/hydroureter and ureteric thickening. Specifically, 
these findings on CT were not able to significantly pre-
dict the presence of tumour compared to the conclusions 
of another study [1]. The combined sensitivity of voided 
urine cytology and CT of 85 % demands the use of URS 
to correctly identify patients with UUTUC. In contrast, 
since 100 % of those with both a normal CT and normal 
voided cytology had benign findings on URS (Table 3), we 
would propose that with clinical judgment, such patients, 
individually risk-stratified, would not require URS. Clearly, 
equivocal results in either modality may necessitate further 
investigation.
A limited analysis of 6/39 (15 %) benign cases after 
URS, who had demonstrated measurable mass or filling 
defects on CT, was undertaken. While the presence of a 
measurable mass is more indicative of malignancy (approx-
imately 2:1 incidence rates in malignant and benign pathol-
ogy, respectively—data not shown), we were unable to 
identify a cut-off size of a mass on CT that would be able 
to discern between benign and malignant findings.
As expected, voided urine cytology correlated well with 
selective cytology, although multivariate analysis suggests 
that selective cytology has statistically superior predic-
tive capability. However, in terms of clinical utility, when 
Table 4  Distribution of ureteroscopic biopsy and post-nephroureter-
ectomy specimen histopathology, stratified according to tumour grade 
and stage
a UUTUC NOS denotes malignant UUTUC not otherwise specified
Variable Ureteroscopic biopsies (%) Nephroureterectomy 
specimens (%)
Total 75 57
 Negative 10 (12) 2 (4)
 UUTUC 65 (87) 55 (96)
Grade
 Total 75 57
  Negative 11 (15) 2 (4)
  UUTUC 
NOSa
5 (7) 4 (7)
  G1 8 (11) 1 (2)
  G2 30 (40) 19 (33)
  G3 21 (28) 31 (54)
Stage
 Total 67 55
  Negative 11 (16) –
  UUTUC 
NOSa
2 (3) 2 (4)
  pTa 45 (67) 15 (27)
  pTis – 4 (7)
  pT1 6 (9) 9 (16)
  pT2 3 (4) 5 (9)
  pT3 – 17 (31)
  pT4 – 3 (6)
Fig. 3  Comparison of ureteroscopic biopsy and post-operative nephroureterectomy specimen grade (left) and stage (right)
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directly compared to selective cytology, this only identified 
10 additional malignant cases over voided cytology. We 
found 85 % of patients with both abnormal CT and abnor-
mal voided cytology had an UUTUC. The same propor-
tion (85 %) was identified in those with abnormal CT and 
abnormal selective cytology. Indeed, our results suggest 
that the addition of selective cytology provides only mar-
ginal additional value. Furthermore, the combination of an 
abnormal selective cytology with subtle CT findings (thick-
ening or hydronephrosis/hydroureter alone) was not suffi-
cient to predict the presence of UUTUC, and direct visual 
observation and/or confirmation with biopsy was critical in 
determining clinical need for nephroureterectomy in these 
cases.
Previous attempts have been made correlating histology 
of ureteroscopic biopsies with nephroureterectomy speci-
mens, but these have been limited by small case numbers 
[3]. We present the largest such series and demonstrate 
that biopsies do correlate with high-grade disease, and 
relatively few cases require upgrading, which may reflect 
more systematic technical approaches to the biopsying of 
tumours.
In the absence of sufficient staging data, we attempted 
to identify the predictive capacity of a high-grade biopsy 
to predict UUTUC invasiveness; however, after multivari-
ate analysis, a high-grade biopsy was unable to predict 
UUTUC invasiveness in our series. Smith et al. [10] sug-
gested that biopsy grade may still be subject to a non-
negligible rate of sampling error, particularly with larger 
tumours, which may in part explain these results. It is pos-
sible that employing narrowband imaging technology, bet-
ter characterised for the diagnosis of bladder TCC, may 
still further improve the identification and biopsy of sus-
pected UUTUC, and this will be an important variable to 
consider in future studies as these ureteroscopes become 
more widely available.
The study is limited by variations between reporting 
radiologist and histopathologists, although all followed 
standard protocols employed at our institution and undergo 
robust quality control measures. Visualisation of lesions 
was used to define the presence of malignancy in some 
cases, and although this was restricted to clear papillary 
lesions, there is an inherent limitation when a biopsy is 
not taken. The study data are also from a single institution, 
with retrospective data collection, and lacked a comprehen-
sive account of potential aetiological risk factors for each 
patient. Future work could benefit from prospective data 
collection, standardised reporting on URS and pathological 
specimens, and multi-institutional data collection, to fur-
ther improve statistical power and clinical applicability.
Conclusion
Our study represents the largest series in the UK to evaluate 
and quantify the predictive capabilities of the pre-operative 
and intra-operative parameters in the diagnosis of UUTUC. 
We support the strategy whereby voided urine cytology and 
CT are useful as screening tools to identify at-risk patients. 
When abnormalities were detected in both pre-operative 
voided cytology and CT, malignancy was confirmed in 
85 % cases. URS is imperative in identifying benign cases, 
particularly when the CT findings represent the only abnor-
mal pre-operative investigation. In the presence of a normal 
CT and voided urine cytology, we propose that a clinical 
judgment can be made for not performing a URS, pro-
vided that individual patient risk factors are also taken into 
account.
Selective urine cytology does not appear to clinically 
improve the prediction of UUTUC. However, URS and 
biopsy remain a valuable confirmatory tool for diagnosis, 
therapy, and guiding surgical management. Our results 
provide quantitation of the current diagnostic tools utilised 
in clinical practice, and in combination with multi-institu-
tional datasets could contribute towards more robust tools 
of risk stratification.
Table 5  Multivariable 
regression analysis of pre-
operative variables predicting 
the presence of UUTUC
Variable Exp(B) 95 % CI p value
Pre-operative factors
Male versus female (ref) 3.025 1.080–8.474 0.035
Age 1.060 1.019–1.102 0.004
Pre-operative urine cytology
 Negative (ref) 0.018
 Atypical 4.980 1.518–16.331 0.008
 Positive 2.557 0.843–10.663 0.090
CT
Normal (ref) 0.014
Hydronephrosis/hydroureter or ureteric thickening 6.643 0.890–49.571 0.065
Filling defect/soft tissue mass 11.675 1.819–71.817 0.009
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